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Aim To present the activities of the Agency for Medicinal 
Products and Medical Devices in the first 5 years of its exis-
tence and to define its future challenges.
Methods Main activities within the scope of the Agency 
as a regulatory authority were retrospectively analyzed for 
the period from 2004-2008. Data were collected from the 
Agency’s database and analyzed by descriptive statistics.
Results The number of issued medicine authorizations 
rose from 240 in 2004 to 580 in 2008. The greatest num-
ber of new chemical and biological entities was approved 
in 2005. The greatest number of regular quality controls 
(n = 5833) and special quality controls was performed in 
2008 (n = 589), while the greatest number of off-shelf qual-
ity controls (n = 132) was performed in 2007. The great-
est number of medicine labeling irregularities was found 
in 2007 (n = 19) and of quality irregularities in 2004 (n = 9). 
The greatest number of adverse reactions was reported in 
2008 (n = 1393). The number of registered medical devices 
rose from 213 in 2004 to 565 in 2008.
Conclusion Over its 5 years of existence, the Agency has 
successfully coped with the constant increase in workload. 
In the future, as Croatia enters the European Union, the 
Agency will have to face the challenge of joining the inte-
grated European regulatory framework.
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The harmonization of Croatian legislation on medicinal 
products with the EU regulations started in 1997, when 
the first Act on Medicinal Products and Medical Devices 
was adopted (1). It was followed by a new Act on Medicinal 
Products and Medical Devices (2) in 2003, which provided 
a legal framework for the establishment of the Agency for 
Medicinal Products and Medical Devices as a regulatory 
authority. Today, the medicinal products in Croatia are reg-
ulated by the Act on Medicinal Products (3) from 2007 and 
its Amendments from 2009 (4), which were adopted dur-
ing the process of harmonization with the EU medicines 
legislation (5-8).
The agency was formed in the fall 2003 from the Croatian 
Institute for the Control of Medicinal Products and the Cro-
atian Institute for the Control of Immunobiologicals, from 
which it inherited the expertise in the control and testing 
of medicinal products, vaccines, and blood products and 
the evaluation of their pharmaceutical quality. The Agency 
also took over a part of the duties of the Ministry of Health 
such as granting marketing authorizations for medicinal 
products, listing medical devices into their register, issuing 
of import/export licenses and manufacturing licenses, with-
drawing of medicinal products and medical devices from 
the market, monitoring drug consumption, and promoting 
rational use of medicines. In 2005, the Agency took over the 
adverse drug reactions monitoring from the Zagreb Clinical 
Hospital Center. It also assumed a greater role in the area 
of medicinal products, immunological medicinal products, 
homeopathic products, and medical devices. This required 
new staff recruitment, additional training for the existing 
staff, and administrative capacity building. Over the first 5 
years of its existence, the Agency has had to deal with the 
inherited backlog and, at the same time, organize admin-
istrative processes accompanying legislative reforms and 
adoption of European regulatory practices. The Agency’s 
vision of the safety of health care products includes tech-
nological and scientific development, globalization in the 
area of the production and distribution of medicinal prod-
ucts, and increasing the expectations of health care profes-
sionals and the wider public (9,10). Moreover, the Agency is 
continuously assessing the benefit/risk ratio for the patient 
(11-14), checking the quality of medicinal products from the 
Croatian market, and defining terms and conditions for the 
production and distribution of medicinal products of legal 
entities based in Croatia. These activities are similar to those 
of most medicines regulatory authorities in Europe (15-18).
The aim of this study is to present the results of the Agen-
cy’s work in the first 5 years of its existence and to define 
the Agency’s future challenges. The key data on Agency’s 
work in the area of medicines authorization, quality con-
trol, adverse reactions monitoring, and regulation of medi-
cal devices were analyzed.
MeThodS
Study design, setting, and period
The main activities within the scope of the Agency as a 
regulatory authority – authorization and quality control of 
medicinal products, monitoring of adverse reactions, and 
regulation of medical devices – were retrospectively ana-
lyzed for the 5-year period (2004-2008). Data were collect-
ed from the Agency’s database.
Agency for Medicinal Products and Medical devices: 
activities and principles
Marketing authorization for medicinal products. Appli-
cations seeking authorization for new finished medicinal 
products have to be submitted to the Agency along with 
the valid registration documentation. The assessment is 
followed by the technical evaluation of quality, safety, and 
efficacy of a medicinal product, which involves a network 
of experts from the Agency, plus external experts. Upon 
successful completion of this procedure, marketing autho-
rization for the medicinal product concerned is granted. 
Statutory period for the authorization procedure is 210 
days. Authorization validity must be renewed every 5 years, 
so the data in this analysis include renewal data as well. 
During the life cycle of a medicinal product, any modifica-
tion in its documentation is considered as the variation of 
the marketing authorization and must be reported to the 
Agency for its approval. Variations are also entered in the 
Agency’s database and thus included in this study.
There are two authorization procedures covered by the 
Agency: national and simplified procedure for EU prod-
ucts. In the national procedure, which is conducted ac-
cording to the relevant Ordinance (19), the Agency per-
forms a complete assessment (evaluation) of medicinal 
product documentation. The simplified procedures are 
conducted according to the special Ordinance (20) and 
refer to the medicines already authorized in the EU by 
the centralized procedure with the European Medicines 
Agency (EMA from December 2009, prior to that EMEA) 
(21-25) or to the medicines authorized in the Member 
States by the decentralized procedure or the mutual 
recognition procedure. These simplified procedures 
FORUM106 Croat Med J. 2010; 51: 104-12
www.cmj.hr
are based on the New Collaboration Agreement between 
Drug Regulatory Authorities in Central and Eastern Europe-
an Countries (nCADREAC) (26). They are subject to shorter 
statutory terms – 150 days for the centralized procedure 
and 180 days for the decentralized and mutual recognition 
procedures.
Medicines quality control. The Agency conducts laboratory 
quality tests for the first batch of medicinal products, fol-
lowing the granting or renewal of the marketing authori-
zation. This is termed special quality control. Products are 
also sampled out of the distribution network once in every 
5 years and their quality is controlled within the Agency. 
This off-shelf quality control is based on the annual sam-
pling plan for marketed medicinal products. Laboratory 
quality control is conducted according to the manufactur-
er’s specification accepted within the approval procedure 
of the medicinal product.
Along with the special quality controls and off-shelf qual-
ity controls from the supply chains, the Agency controls 
every imported batch of medicinal products in the process 
of regular quality control. For the EU products, the regu-
lar control is based on the reviews of the manufacturers’ 
certificates of analysis and the reviews of the packaging 
of the presented finished product. For all other medicines, 
the regular quality control is performed by the laborato-
ry quality tests. After conducting regular quality control of 
the imported batches, the Agency issues an approval for 
the import of the controlled batch. The Agency can also 
perform an extraordinary quality control in the case of ur-
gency (in the event of contingencies). Irregularities can be 
singled out from the laboratory quality control findings or 
they can be related to inadequate product packaging, har-
monization of patient information leaflet, or outer and in-
ner labeling with the current updated product registration 
documentation.
The Agency is also required to withdraw batches of medic-
inal products based on the evaluation of field reports on 
quality defects and/or adverse reactions from the country 
or abroad (27). For prompt field-reporting on adverse reac-
tions and quality defects of medicinal products and medi-
cal devices, the Agency has made available a 24-hour tele-
phone line.
Pharmacovigilance and adverse reactions monitoring. 
Pharmacovigilance activities in the Agency can be de-
fined as the control and prevention of the risks caused 
by the adverse reactions and includes data from 
spontaneous reports on adverse reactions, registration 
documentation, and laboratories performing quality con-
trol on distributed medicinal products. The pharmacovigi-
lance system is based on the legal obligation of health care 
professionals to spontaneously report to the Agency any 
adverse reaction on medicinal products and the obligation 
of the Agency to examine and follow up the reported case. 
Adverse reactions to vaccines must be reported to both 
the Agency and the Croatian National Institute of Public 
Health. For each reported adverse reaction, the notifying 
party is given a personalized expert opinion by the Agen-
cy. The Agency is a member of the World Health Organi-
zation (WHO) Programme for International Drug Monitor-
ing (28), and reports of adverse reactions in the Republic 
of Croatia are regularly forwarded to the adverse reactions 
database of the WHO.
Regulation of medical devices. The notified body provides 
an assessment of the product compliance, on the basis 
of which the product receives the CE label of conformity 
(French: conformité européenne). The compliance assess-
ment procedure for medical devices is not carried out by 
agencies for medical devices; instead, they are delegated 
to the private sector, ie, to notified bodies, registered by 
the European Commission for such procedures (29-34). 
Once a medical device has received its CE label (35,36), it 
can freely be circulated within the whole European market, 
while agencies for medical devices supervise the market 
and the vigilance of medical devices (37,38), as well as the 
private companies. Pursuant to the European legislation, 
medicinal products have been separated from medical de-
vices in Croatia, and the new Act on Medical Devices (39) 
was passed by the Croatian Parliament on October 1, 2008. 
After the death of 23 dialysis patients in October 2001 
due to irregularities in the quality of a dialysis equipment 
(40,41), Croatia assumed the obligation to officially register 
all medical devices prior to their arrival on the market. The 
registration is supervised by a special commission.
data extraction
We collected the information from the Agency’s medici-
nal products and medical devices databases. Information 
related to medicines approvals includes marketing autho-
rizations for finished medicinal products as the Agency’s 
output documents. Absolute numbers are shown for the 
authorizations for new medicinal products, renewals, and 
variations of finished medicinal products in the five-year 
period 2004-2008, as well as transfers of authorizations 
in 2008, which include administrative transfers of autho-
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rization from one entity to another and which were ear-
lier treated as variations. During the analyzed period, each 
pharmaceutical form, potency, or packaging of one active 
substance received a separate marketing authorization 
for a finished medicinal product. Also, the number of new 
chemical and biological entities licensed in Croatia for the 
first time in the form of finished medicinal products was 
taken from databases for each year.
Data concerning medicines quality control are expressed 
as the number of findings in the laboratory quality con-
trol or approvals for the import of finished products based 
on the regular quality control reports. The study also used 
the information from the Agency’s databases on adverse 
reactions reported by health care professionals, physicians, 
and pharmacists. We analyzed the information over the 
four-year period 2005-2008 because the Agency has been 
responsible for monitoring the safety of medicines since 
March 2005. The number of adverse reactions to conven-
tional medicinal products, especially vaccines, was singled 
out. The number of medical devices registered in the Medi-
cal Devices Register of the Agency (2004-2008) was also 
obtained from the Agency’s medical device database. Data 
were analyzed by descriptive statistics.
ReSulTS
Marketing authorization for medicinal products
In the period from 2004 to 2008, a steady increase in the 
number of authorization and renewal issuances was ob-
served. Also, a continuous increase in resolved variation 
cases was recorded. The number of resolved transfers of 
authorizations was first recorded in 2008 (n = 112), because 
they were previously treated as variations. The number of 
newly authorized active substances licensed in Croatia for 
the first time in the form of finished medicinal products in-
creased with the total increase in authorizations issued for 
finished medicinal products, a tendency particularly no-
ticeable in 2005. The number of marketing authorizations 
for medicinal products in the period 2004-2008 is sum-
marized in Table 1. In 2008, 76.1% of marketing authoriza-
tions were granted on the basis of national procedure, and 
23.9% according to a simplified authorization procedure 
for EU products depending on the procedure conducted 
in the EU (mutual recognition procedure, decentralized 
procedure, centralized procedure). This analysis was made 
for the first time in 2008 because that was the year when 
the Ordinance regulating simplified procedures (20) came 
into force.
Medicines quality control
Special quality control was carried out on every first batch 
of manufactured medicinal products and 51 findings were 
issued in 2004. The number of findings increased in 2005 
and 2006, followed by a slight decrease in 2007 and a new 
increase in 2008 (n = 589). In 2005, the Agency started per-
forming off-shelf quality control, and that year 41 medi-
cines were sampled out of the market by pharmaceutical 
inspectors. In 2006, there was slight increase in these con-
trols, while in 2007 and 2008 the number of quality con-
trols out of the pharmacies and wholesalers increased to 
132 and 120, respectively, pursuant to the annual sampling 
plan (Figure 1).
Over the years, the number of approvals for the import of 
medicine batches from the EU to Croatia was rising, and so 
was the number of newly authorized medicinal products. 
Therefore, there was an increase in the number of regular 
quality controls conducted by the Agency (from 3327 in 
2004 to 5833 in 2008) (Figure 2). During the issuance of ap-
TABle 1. The number of marketing authorizations issued by the Agency for Medicinal Products and Medical devices, Croatia, in the 
period 2004-2008
2004 2005 2006 2007 2008
Marketing authorizations 248 452 254 510 598
Classification of marketing authorization by the 
type of authorization procedure*
CP  –  –  –  –  33
DCP  –  –  –  –  59
MRP  –  –  –  –  51
National procedure  –  –  –  – 455
Renewals 177 270 197 267 367
Variations  56 352 450 651 624
Transfers  –  –  –  – 112
Number of authorized new chemical and biological entities  24  44  35  41  40
*Abbreviations: CP – simplified procedure for products authorized in the eu by centralized procedure; dCP – simplified procedure for products 
authorized in the eu by decentralized procedure; MRP – simplified procedure for products authorized in the eu by mutual recognition procedure.
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provals for the import and the findings of laboratory qual-
ity controls performed on first batch products and medi-
cines sampled from the market, quality defects and defects 
in inner and outer packaging and instructions for patients 
were also documented. There were 9 findings of substan-
tial quality defects in 2004, 5 quality defects in 2005 and 
2007, 6 quality defects in 2006, while in 2008 no irregularity 
in the quality was found. Eleven medicine labeling irregu-
larities were detected in 2004, 5 labeling irregularities each 
in 2005 and 2006, followed by an increase of 19 irregulari-
ties in 2007 and 18 in 2008 (Figure 3).
Adverse reactions monitoring
The role of the National Pharmacovigilance Center was 
taken over by the Agency in 2005, when 498 adverse reac-
tions were reported and documented. In 2006 and 2007, 
the number of reported adverse reactions constantly in-
creased and in 2008 rose to 1393 (Figure 4). The total num-
ber of notified adverse reactions increased by 180% in 
2008 compared with 2005.
Regulation of medical devices
At the start of the Agency’s work in 2004, a total of 213 
medical devices were registered in the official Register of 
Medical Devices. In the following years, the number of reg-
Figure 1.
Medicinal product quality control reports issued by the Agency for Me-
dicinal Products and Medical devices, Croatia, in the period 2004-2008. 
Gray bars – special quality control of the first batch; closed bars – off-
shelf quality control.
Figure 2.
 Agency for Medicinal Products and Medical devices, Croatia, in the peri-
od 2004-2008: regular medicinal product quality control reports of every 
imported batch in Croatia.
Figure 3.
Agency for Medicinal Products and Medical devices, Croatia, in the peri-
od 2004-2008: deficiencies of medicinal products. Gray bars – non-com-
pliance in labeling and patient information leaflet; striped bars – sub-
stantial quality defects.
Figure 4.
Number of spontaneous adverse reactions reported to the Croatian 
Agency for Medicinal Products and Medical devices in the period from 
2005-2008. Striped bars – number of spontaneous adverse reactions re-
ported for medicinal products; gray bars – number of spontaneous ad-
verse reactions reported for vaccines.
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istered medical devices constantly increased (from 342 in 
2005 to 565 in 2008) (Figure 5).
dISCuSSIoN
In the first 5 years of its existence (from 2004-2008), the 
Agency issued 2062 marketing authorizations, 1278 re-
newals, and 2133 variations to the authorizations for fin-
ished medicinal products. According to the statistical data 
available on the Web site of the German medicines regu-
latory agency, the Federal Institute for Drugs and Medical 
Devices (BfArM), in the same period issued 12 096 autho-
rizations (42). Greater number of issued marketing autho-
rization in Germany from 2004-2008 could be explained 
by the difference in market size (number of patients using 
medicines) and the fact that in the first 5 years of its exis-
tence Croatian Agency had to develop a number of dif-
ferent internal procedures along with all the other duties. 
On the other hand, European Medicines Agency in the 
first 5 years of its activity (1995-2000) issued 126 market-
ing authorizations and 856 variations (18). Smaller num-
ber of medicines authorized by EMA in comparison with 
the Croatian Agency can be explained by the fact that 
EMA conducts more complex centralized authorization 
procedure for all EU member states, which is based on a 
specific evaluation of medicinal products and provision of 
scientific advice (43). Also, the Croatian Agency had had 
a sizeable backlog of applications for marketing authori-
zations, variations, and renewals already upon its estab-
lishment. At the same time, it had had to cope with the 
inflow of new applications for which the statutory term of 
210 days had to be strictly observed (19). The EMA did not 
have any backlog because it was a completely new insti-
tution, which is why there were no renewals in the EMA 
during its first 5 years.
In the first year after its establishment (2004), the Agency is-
sued 248 marketing authorizations, while the Montenegrin 
Agency for Medicines and Medical Devices issued 147 au-
thorizations in the first year of its existence (2009) (44). This 
could be explained by the differences in market size and 
level of expertise/experience of these two agencies. The 
Croatian Agency was created from two national health in-
stitutes and inherited a considerable amount of expertise, 
while the Montenegrin Agency started without previous 
experience. This presumption leads to the conclusion that 
one of the most important factors in the performance of 
medicines agencies is professional experience and exper-
tise in specific regulatory issues. For this reason, co-opera-
tion between medicines agencies through the exchange 
of the best practices and regulatory knowledge is crucial 
for developing their expert and administrative capacity.
The number of resolved cases in the Croatian Agency was 
growing each year (as was the influx of new molecules), 
being the greatest in 2005, which can be explained by the 
improving work routine of the Agency, notably its Experts 
Committee’s endeavor to solve the backlog as soon as pos-
sible. In the recent years, the number of finished product 
authorizations has risen, but this increase is no longer nec-
essarily accompanied by an increase in new molecules on 
the Croatian market, but rather by a greater number of ge-
neric medicines that have appeared after the expiry of pat-
ent protection for a certain number of proprietary medici-
nal products. In the last analyzed year (2008), the Agency 
issued 598 marketing authorizations, similarly to 695 au-
thorizations issued by the Serbian national agency (45).
In 2008, the overwhelming majority of cases were resolved 
by the “national procedure” (19,46), with only a minor num-
ber of cases resolved by the simplified European proce-
dures (nCADREAC). The simplified authorization proce-
dures for the EU products brought several advantages: the 
summary of product characteristics, the patient informa-
tion leaflet, and its labeling on the outer and inner packag-
ing are harmonized between the EU member states and 
Croatia; the registration procedure is shorter; and the pa-
tient can get a new medicinal product, whether innova-
tive or generic, without unnecessary delay. This is why in 
the following years the Agency expects a considerable 
increase in applications for simplified authorization 
procedure, which will shorten the authorization 
Figure 5.
Number of medical devices registered in the Medical devices Register of 
the Agency for Medicinal Products and Medical devices, Croatia, in the 
period 2004-2008
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process and lead to an increased availability of medicines 
in Croatia.
In the first 5 years of its existence, the Agency performed 
1716 special quality controls of the first batch of medici-
nal products after granting the authorization, 345 off-
shelf quality controls, and 19 802 regular quality controls 
of imported batches. On the other hand, the Medicines 
and Healthcare products Regulatory Agency as a national 
Agency of the United Kingdom performed 11 269 quality 
controls in the five-year period from 2002-2006 (47). The 
main difference between these two quality controls sys-
tems is that Croatian system is more oriented on the pre-
authorization control and the UK system on the market 
surveillance (with sampling and testing of strictly selected 
medicinal products at, or destined for, the UK market).
The quality defects found with the manufactured product 
batches are largely related to the discrepancies in product 
labeling and patient information leaflet. This has been a 
growing tendency in the past two years, whereas the num-
ber of quality defects among medicinal products from the 
distribution network and first batch has been on decline. 
These discrepancies in the product information of new 
medicines are associated with the manufacturers’ inability 
to furnish the manufactured batch in accordance with ap-
proved variations in due time.
The number of spontaneously reported adverse reactions 
in 2008 rose by 180% compared with 2005. Although in 
2006 and 2007 an approximately equal rate of adverse re-
actions to conventional medicinal products was record-
ed, in 2008 there was a difference in that rate due to an 
increase in the number of adverse reactions to vaccines 
(n = 734). This can be attributed to the introduction of new-
ly authorized vaccines in the prophylactic practice and a 
sudden increase in the number of adverse reactions to the 
mumps component of the combination vaccine (MMR – 
measles, mumps, and rubella), the consequence of which 
was the exclusion of this vaccine from primo vaccination 
in the mandatory vaccination calendar. However, the over-
all increase in spontaneous reporting is certainly a result 
of the Agency’s developing partnership with health care 
professionals in the area of spontaneous reporting. For this 
purpose, in 2005 the Agency started to organize work-
shops for health care professionals, hitherto more than 60, 
on spontaneous reporting.
WHO Programme for International Drug Monitoring 
(28) coordinated from the Uppsala Monitoring Cen-
tre in Sweden has compared the number of spontaneous 
reports between 96 countries in the five-year period from 
2004 to 2009. Croatia ranked 19th, with about 150 adverse 
reactions per million inhabitants per year. New Zealand 
ranked first, with more than 1100 reported spontaneous 
adverse reactions per million inhabitants per year (28). This 
indicates low awareness of the importance of reporting 
in Croatia in comparison with some other countries. This 
is also one of the reasons why the Agency must continue 
with the education of Croatian health care professionals.
Evaluation of medicines safety profile is crucial because 
the Agency is also required to withdraw medicinal prod-
ucts due to safety reasons. Nevertheless, in most cases a 
medicinal product is recalled at the request of the mar-
keting authorization holder, as it happened in September 
2004 with rofecoxib (Vioxx), where the manufacturer, due 
to severe cardiovascular adverse reactions detected during 
the post-marketing studies, globally recalled the medicinal 
product and requested a repeal of its authorization in all 
countries (48,49).
From its establishment, the Agency has registered 2001 
medical devices in total. Over the five-year period, a steady 
increase in the number of medical devices in the Medical 
Devices Register has been recorded, and we can conclude 
that these products are well controlled on the Croatian 
market. Registration of medical devices prior to market-
ing is a specific feature of Croatian legislation that is going 
to be changed in the process of harmonization with the 
EU legislation because it is not in accordance with the free 
movement of goods (although it enables stricter market 
control of these products).
Looking at the future challenges and considering the fact 
that the regulatory framework for medicinal products in 
Croatia is well aligned with the acquis communautaire, 
it is reasonable to expect that upon Croatia’s accession 
to the EU, the Agency will join the integrated European 
regulatory framework without major difficulties. Howev-
er, the Agency faces several challenges – one of them is 
that the Croatian representatives in EMA committees will 
have to actively participate in the evaluation of new me-
dicinal products authorized via the centralized procedure, 
for which Agency experts must still gain some specialized 
knowledge. Croatia will thus be expected to participate in 
the “work sharing,” which is one of the basic principles un-
derlying the functioning of the European regulatory sys-
tem and to take an active role in inter-governmental work 
on new legislation for medicinal products and medical de-
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vices. In order to achieve this, the Agency will have to maxi-
mize its international co-operation and reorganize its ac-
tivities. As part of the preparations for EU membership, the 
Agency has already established international cooperation 
with various European institutions, notably the EMA within 
the European Commission’s Instrument for Pre-Accession 
Program through which the Agency’s experts have the ob-
server status in certain EMA committees.
It can be concluded that due to its expert capacity, after 
the 5 years of experience, the Agency is able to process all 
requests for its services for the Croatian market. The current 
challenge is the massive inflow of new applications con-
cerning variations in the existing marketing authorizations 
for the finished medicinal products. It should also be noted 
that the Agency is preparing to reorganize its activities due 
to the Croatian accession to the EU, which is a major chal-
lenge for its future work.
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